Literature DB >> 10094880

Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors.

A H Lane1, M M Lee, A F Fuller, D J Kehas, P K Donahoe, D T MacLaughlin.   

Abstract

OBJECTIVES: In this study we evaluated changes in serum Müllerian inhibiting substance (MIS) concentration in a large number of patients with granulosa cell tumors (GCT) to determine whether MIS is elevated at the time of presentation and whether MIS is an index of successful surgical resection and management of recurrences.
METHODS: We retrospectively reviewed MIS levels from 17 subjects prior to tumor resection and studied serial MIS samples from 56 subjects following initial tumor resection. Clinical follow-up information was available for 36 of those with postoperative MIS values. Serum MIS was measured by an ELISA. MIS values were compared to a combination of normative values previously established in our laboratory and from more recently obtained samples from older pre- and postmenopausal women, using this assay.
RESULTS: Serum MIS was elevated pre-operatively in 6 of 8 (75%) subjects with juvenile GCTs and in 7 of 9 (78%) of those with adult GCTs relative to age-matched controls (76% for both types combined). Post-operative clinical correlation was available for 36 patients. There was no clinical recurrence in 21 subjects with normal or undetectable postoperative values, and incompletely resectable tumor or recurrence was identified in 6 of 15 patients with elevated postoperative values.
CONCLUSIONS: The results of this study demonstrate that postoperative serum MIS concentrations may be used to evaluate the completeness of tumor removal following initial surgery and that serial MIS determinations may allow the detection of recurrences. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10094880     DOI: 10.1006/gyno.1998.5290

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  First assessment of menstrual cycle function and reproductive endocrine status in Samoan women.

Authors:  G Lambert-Messerlian; M B Roberts; S S Urlacher; J Ah-Ching; S Viali; M Urbanek; S T McGarvey
Journal:  Hum Reprod       Date:  2011-06-15       Impact factor: 6.918

Review 2.  Anti-Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?

Authors:  Akira Iwase; Tomoko Nakamura; Satoko Osuka; Sachiko Takikawa; Maki Goto; Fumitaka Kikkawa
Journal:  Reprod Med Biol       Date:  2015-11-23

Review 3.  [Leydig cell, Sertoli cell and adult granulosa cell tumors].

Authors:  F Bremmer; S Schweyer
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

4.  Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.

Authors:  Rafael Pieretti-Vanmarcke; Patricia K Donahoe; Lisa A Pearsall; Daniela M Dinulescu; Denise C Connolly; Elkan F Halpern; Michael V Seiden; David T MacLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

Review 5.  [Sex cord gonadal stromal tumors].

Authors:  F Bremmer; C L Behnes; H-J Radzun; M Bettstetter; S Schweyer
Journal:  Pathologe       Date:  2014-05       Impact factor: 1.011

6.  Serum Müllerian Inhibiting Substance/anti-Müllerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology.

Authors:  Henry L Chang; Nima Pahlavan; Elkan F Halpern; David T MacLaughlin
Journal:  Gynecol Oncol       Date:  2009-04-08       Impact factor: 5.482

7.  Juvenile granulosa cell tumor of the ovary presenting with pleural effusion and ascites.

Authors:  Harpreet Kaur; Rashmi Bagga; Subhash Chandra Saha; Shalini Gainder; Radhika Srinivasan; Amit K Adhya; Lakhbir Kaur Dhaliwal
Journal:  Int J Clin Oncol       Date:  2009-02-20       Impact factor: 3.402

8.  The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand.

Authors:  Imed Salhi; Sylvie Cambon-Roques; Isabelle Lamarre; Daniel Laune; Franck Molina; Martine Pugnière; Didier Pourquier; Marian Gutowski; Jean-Yves Picard; Françoise Xavier; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Biochem J       Date:  2004-05-01       Impact factor: 3.857

9.  Smad1-Smad5 ovarian conditional knockout mice develop a disease profile similar to the juvenile form of human granulosa cell tumors.

Authors:  Brooke S Middlebrook; Karen Eldin; Xiaohui Li; Sujatha Shivasankaran; Stephanie A Pangas
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

Review 10.  Anti-müllerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development.

Authors:  Marie Lindhardt Johansen; Casper P Hagen; Trine Holm Johannsen; Katharina M Main; Jean-Yves Picard; Anne Jørgensen; Ewa Rajpert-De Meyts; Anders Juul
Journal:  Int J Endocrinol       Date:  2013-12-03       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.